• Mashup Score: 1

    In what one expert called a ‘major breakthrough,’ researchers combined telephone counseling with home blood pressure telemonitoring for stroke survivors with uncontrolled hypertension.

    Tweet Tweets with this article
    • In what could be a major breakthrough, researchers combine phone counseling + home BP telemonitoring for stroke survivors with uncontrolled hypertension. https://t.co/DFRJHLnrSK #ISC20

  • Mashup Score: 1

    Do special ambulances designed to accelerate acute stroke care also improve functional outcomes down the road? Results of the B_PROUD trial suggests they may.

    Tweet Tweets with this article
    • B_PROUD trial suggests ambulances designed for acute stroke care may improve functional outcomes. https://t.co/w5lLe3dRA2 ##ISC20 https://t.co/ztunlJ0ygO

  • Mashup Score: 0

    Switching from alteplase to tenecteplase as the routine thrombolytic in acute ischemic stroke is having multiple benefits for at least one US hospital system, researchers report.

    Tweet Tweets with this article
    • Switching from alteplase to tenecteplase for stroke is having multiple benefits for one US hospital system. https://t.co/LStlTkydB6 #ISC20

  • Mashup Score: 3

    LOS ANGELES ― The antiplatelet agent cilostazol (Pletal, Otsuka), used to treat symptoms of intermittent claudication for patients with peripheral vascular disease, may be effective in preventing restenosis after carotid stenting, a new study suggests. For the primary endpoint, analysis showed a trend toward less in-stent restenosis after carotid stenting in treated patients,…

    Tweet Tweets with this article
    • The antiplatelet agent cilostazol may be effective in preventing restenosis after carotid stenting, a new #ISC20 study suggests. https://t.co/TfVmf84MGc

  • Mashup Score: 2

    Total yearly payments increased tenfold over a 6-year period, with the focus shifting from drugs to devices.

    Tweet Tweets with this article
    • "Over time the numbers have gone up, which one would expect, given that a lot of the breakthroughs in our field have come from pharmaceutical- and device-sponsored trials." @DrSaccoNeuro #ISC20 @krishnaomc https://t.co/4snVNyr9Eq